- Home
- ACC 2019: Duration Of Diabetes And Cardiorenal Efficacy Of Liraglutide And Semaglutide - Prof Subodh Verma
ACC 2019: Duration Of Diabetes And Cardiorenal Efficacy Of Liraglutide And Semaglutide - Prof Subodh Verma
Topic:
- Prevention
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
Prof Subodh Verma (University of Toronto, Toronto, CA) discusses his poster presented at the ACC 2019 entitled duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide - a post hoc analysis of the LEADER and SUSTAIN-6 Clinical Trials.
Target Audience
- Cardiologists
- Diabetologists
- Nephrologists
This course is not accredited
Related Courses
Advancements in Triglyceride-lowering Therapies
- 1.00
Published:
Learning objectives
- Recall the primary and secondary outcomes from key triglyceride-lowering trials presented during ESC 2024
- Discuss the current and future implication of trial results to clinical management and practice guidelines
Elevating Understanding and Management of Hypertriglyceridemia
- 1.25
Published:
Learning objectives
- Understand HTG as a risk factor for acute and chronic illness
- Describe current guideline directed management of HTG
- Recognise the gaps and challenges present in current guideline directed management of HTG
- Recall emerging trial data for novel pharmacological targets
- Use guidelines, trial data & expert opinion to develop individualised treatment strategies for high-risk patients